Comprehensive Bladder Preservation Therapy on Patients With Muscle Invasive Bladder Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

February 28, 2023

Primary Completion Date

February 29, 2024

Study Completion Date

February 28, 2026

Conditions
Urinary Bladder Neoplasms
Interventions
DRUG

Tislelizumab Injection

After patient recruitment, every patient first receives a regimen of tislelizumab injection 200 mg every time , q3w, 4 times in total. Then all patients, if operable, undergo TURBT. The first day after TURBT, patients again start to receives a regimen of tislelizumab Injection 200 mg every time , q3w, 4 times in total. Meanwhile, on the eighth day after TURBT, patients start to receive radiotherapy. The total radiation dosage is 50.4 Gy (patients receive radiotherapy 28 times, dosage being 1.8 Gy every time), with the total radiation dosage on pelvis area being 45 Gy and total radiation dosage on bladder area being 50.4 Gy.

PROCEDURE

Transurethral resection of bladder tumor

After the initial tislelizumab injection regimen, patients undergo clinical assessment and receive transurethral resection of bladder tumor if operable.

RADIATION

Adjuvant radiotherapy

On the eighth day after TURBT, patients start to receive radiotherapy. The total radiation dosage is 50.4 Gy (patients receive radiotherapy 28 times, dosage being 1.8 Gy every time), with the total radiation dosage on pelvis area being 45 Gy and total radiation dosage on bladder area being 50.4 Gy.

Trial Locations (1)

710061

First Affiliated Hospital of Xian Jiaotong University, Xi'an

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

BeiGene

INDUSTRY

lead

First Affiliated Hospital Xi'an Jiaotong University

OTHER